Chimeric antibody receptors (CARs): Driving T-cell specificity to enhance anti-tumor immunity
Partow Kebriaei · Frontiers in Bioscience-Scholar · 2011
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
Frontiers in Bioscience-Scholar · IMR Press · article · 2011
Abstract
Adoptive transfer of antigen-specific T cells is a compelling tool to treat cancer. To overcome issues of immune tolerance which limits the endogenous adaptive immune response to tumor-associated antigens, robust systems for the genetic modification and characterization of T cells expressing chimeric antigen receptors (CARs) to redirect specificity have been produced. Refinements with regards to persistence and trafficking of the genetically modified T cells are underway to help improve the potency of genetically modified T cells.
Clinical trials utilizing this technology demonstrate feasibility, and increasingly, antitumor activity, paving the way for multi-center trials to establish the efficacy of this novel T-cell therapy.
Open the resolved locator · 10.2741/282
Metadata licence: OpenAlex metadata (CC0)